Celltrion HealthCare France clinical trials
Acquired by Celltrion, Dec 28, 2023 · source ↗
The registry lists 3 studies whose lead sponsor is Celltrion HealthCare France. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 23, 2026.
Before and after it joined Celltrion
- First submitted before Celltrion HealthCare France became part of Celltrion
- 1
- First submitted after Celltrion HealthCare France became part of Celltrion
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Celltrion HealthCare France3 studies
Something wrong with this grouping? Tell us on the Celltrion page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Celltrion studies →
- ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab BiosimilarRecruitingNCT07425639
Sponsor listed in the registry: Celltrion HealthCare France · First submitted after Celltrion HealthCare France became part of Celltrion
- ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab BiosimilarRecruitingNCT06997055
Sponsor listed in the registry: Celltrion HealthCare France · First submitted after Celltrion HealthCare France became part of Celltrion
- Yuflyma® (Adalimumab), Patient Experience After SwitchingStatus unknownNCT05427942
Sponsor listed in the registry: Celltrion HealthCare France · First submitted before Celltrion HealthCare France became part of Celltrion